ABT · Abbott Laboratories

The thesis

Abbott Laboratories' third-quarter report on 21 October 2026 delivered the acceleration the prior note was waiting for, but not the full-year outcome. Comparable sales growth rose to 7.0% from the second quarter's 4.8%, yet Abbott cut its 2026 comparable growth guide to about 6.0% from the 6.5%–7.5% range reaffirmed on 16 July 2026. The shares closed at $103.10 on 27 October 2026, 19.1% below the $127.42 52-week high, and remain more likely to lag the S&P 500 than lead it until the January 2027 report shows whether growth holds.

Abbott's release shows sales of $13,013 million, up 14.5% reported and 7.0% comparable, with adjusted earnings per share (EPS) of $1.42 against a $1.38–$1.46 guide. The EPS guide was narrowed to $5.50–$5.55 from $5.45–$5.60, and fourth-quarter adjusted EPS is guided to $1.62–$1.67. MarketBeat reported the shares fell about 4% in early trading on the day.

Abbott also announced plans to spin off its Nutrition business, about $8.5 billion in annual sales, as an independent public company by the end of 2027. The narrative is maturing: the recovery story is well known, the main hard fact has now been reported, and the 27 October 2026 Argus Research downgrade to Hold shows analyst enthusiasm cooling.

Bullish and bearish views on Abbott Laboratories

The bull case on Abbott Laboratories (ABT), in brief: Comparable growth accelerated sharply. The bear case: Full-year growth guide was cut.

Bull case

• Comparable growth accelerated sharply. Q3 comparable growth was 7.0% against 4.8% in Q2 (Abbott, 16 July 2026 and 21 October 2026). Adjusted EPS of $1.42 landed inside the guided range.
• Electrophysiology and cancer diagnostics lead. Electrophysiology comparable growth was 15.5% in Q3 versus 13.4% in Q2. Cancer Diagnostics, which includes Exact Sciences, grew 13.8% comparable (Abbott, 21 October 2026).
• Nutrition returned to growth. Nutrition comparable sales rose 4.9% in Q3, and Diagnostics rose 6.4%, two lines the second-half plan relied on (Abbott, 21 October 2026).
• Fourth-quarter earnings guide is firm. Abbott guided Q4 adjusted EPS to $1.62–$1.67 and kept the midpoint of the full-year EPS range (Abbott, 21 October 2026).
• Sell-side targets sit above the price. After the report, Baird's target is $123, Citi's $122, RBC's $125, BTIG's $125 and Wells Fargo's $120 (Benzinga, 22 October 2026 and 23 October 2026). All exceed the $103.10 close.
• New cancer-test launches continue. Abbott made its Oncodetect molecular residual disease test commercially available on 26 October 2026, after presenting data at the ESMO congress on 23 October 2026.

Bear case

• Full-year growth guide was cut. About 6.0% comparable growth sits below the 6.5%–7.5% range Abbott reaffirmed in July (Abbott, 21 October 2026). The prior note named a cut as a condition that would break the recovery case.
• Analysts trimmed targets and ratings. Citi, RBC, JPMorgan, TD Cowen and BTIG lowered targets on 22 October 2026, and Argus Research downgraded the shares to Hold on 27 October 2026 (company news).
• Glucose monitoring growth slowed. Continuous glucose monitor comparable growth was 7.7% in Q3 against 9.5% in Q2 (Abbott, 21 October 2026).
• Shares have not rerated. The close of $103.10 on 27 October 2026 compares with $102.97 on 14 October 2026 and $102.61 on 18 September 2026, so the shares trade in the September range. The 3-month price change is -1.8%.
• Spin-off adds execution and cost. Abbott expects one-time transaction charges not yet quantified, and the distribution depends on a Form 10 registration and board approval. About 1,700 infant-formula suits also remain with no disclosed reserve.

Price setup

The last completed daily close was $103.10 on 27 October 2026. That is 19.1% below the $127.42 52-week high and 1.8% below the close three months earlier. The 14-day Relative Strength Index (RSI), a 0–100 momentum gauge, reads 64.0, up from 27.2 on 1 October 2026 and 56.1 on 14 October 2026, so the shares have recovered from oversold without breaking above the September range.

The prior invalidation level remains the 4 May 2026 closing low of $87.54; the $96.69 close of 1 October 2026 is the nearer low. No crowding signal is visible in the shares themselves: the price is not extended above a rising average, and the sell-side targets cited above all sit above it. The earnings date has passed, and the next report is not confirmed.

Catalysts, next 30 days

• No dated company event is confirmed inside the next 30 days.
• ~31 December 2026 (est.): Libre Duo 10 Day US launch, guided "later this year", in the glucose monitor line that grew 7.7% comparable in Q3.
• ~21 January 2027 (est.): Q4 2026 report and 2027 guidance, which Abbott said it will issue in January.
• 31 December 2027: Abbott's stated target for completing the Nutrition distribution.

What would change the view

The case breaks if fourth-quarter comparable growth falls below the third quarter's 7.0%, or if 2027 guidance implies a slower pace than 2026. A daily close below $87, under the 4 May 2026 closing low of $87.54, would also end it.

A stronger read would need fourth-quarter comparable growth at or above 7.0% with the 6.0% full-year figure met, plus steady electrophysiology growth near the 15.5% of Q3. Quantified spin-off charges and the Form 10 filing would add facts either way.

What it trades with

Abbott trades with large-cap medical device and diagnostics companies, and the 17 July 2026 Intuitive Surgical drop of 11% on a warning about insurance changes shows procedure-volume worries can move the group. The Nutrition spin-off adds a separate driver: the infant-formula and adult-nutrition business that will leave Abbott carries the litigation overhang, and its exit would change what the remaining medtech and diagnostics company is valued against.